Agomab adds two members to its board of directors

Agomab Therapeutics NV (Nasdaq: AGMB) announced that shareholders approved the appointments of Marino Garcia and Naimish Patel, M.D., as non-executive members of its board of directors at a Special and Extraordinary General Shareholders' Meeting held on September 11, 2026.

The clinical-stage biopharmaceutical company, focused on fibro-inflammatory diseases, said shareholders also approved the consolidation and split adjustment of outstanding pre-initial public offering warrants, aligning them with the share split implemented in connection with Agomab's IPO in February 2026.

Tim Knotnerus, Chief Executive Officer of Agomab, said both appointees "bring exceptional and complementary experience that will be highly valuable as we continue to advance our portfolio of potential disease-modifying therapies for fibro-inflammatory diseases."

Garcia said he looks forward to working with the board and management team to advance the company's strategy. Patel noted he intends to bring experience in translational medicine and clinical development to support the company's progress.

You May Also Be Interested In

• Agomab adds two members to its board of directors
• Vertical Data agrees to buy 4.5 MW Sweden data center site
• Tenon Medical raises $2.87M through warrant inducement deal